简体
  • 简体中文
  • 繁体中文

热门资讯> 正文

Vyome为其主要临床项目VT-1953提交孤儿药物状态报告

2026-02-11 20:07

  • Acceptance of Orphan Drug Status would confer certain anticipated US Market Exclusivity, R&D tax benefits, and PDUFA fee waiver of approximately $3M
  • Independent third-party assessment estimates a current VT-1953 valuation of approximately $455M today and ~$1B after a successful Phase 3 study
  • FDA interactions planned in Q2 2026 for the Phase 3 protocol based on earlier announced positive Phase 2 results

风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。